{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:13:47Z","timestamp":1790108027294,"version":"4.0.1"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Human immunodeficiency virus (HIV) and COVID-19 continue to pose significant global public health challenges. Although vaccination is essential for preventing COVID-19 in people with HIV (PWH), evidence on the immunogenicity and safety of booster doses remains limited. This systematic review aimed to assess the immunogenicity and safety of COVID-19 booster vaccination in PWH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive literature search in PubMed, EMBASE, and the Cochrane Library. Eligible studies included PWH who had received three or more doses of a COVID-19 vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Across 54 included studies, 4,685 of 5,229 PWH achieved seroconversion following a third or subsequent COVID-19 vaccine dose\u2014an improvement over rates observed after the primary vaccine series. In 23 studies comparing 2,284 PWH with 1,813 healthy controls (HC), no significant differences in seroconversion rates were found (p \u2265 0.05). Among PWH, 22 studies reported significantly higher seroconversion rates in individuals with CD4<jats:sup>+<\/jats:sup> T cell counts &amp;gt;200 cells\/mm\u00b3 compared to those with counts &amp;lt;200 cells\/mm\u00b3. Booster vaccination enhanced CD4<jats:sup>+<\/jats:sup> T cell responses to levels comparable to HC, although CD8<jats:sup>+<\/jats:sup> T cell responses remained markedly lower. Five studies reported adverse events following booster doses, none of which were classified as serious.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>COVID-19 booster vaccination is effective in enhancing immune protection and reducing severe disease in PWH. Optimal vaccine dosing is especially important in individuals with low CD4<jats:sup>+<\/jats:sup> T cell counts. Tailoring booster strategies may improve seroconversion and overall immune response in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42024605151<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1668576","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:45:09Z","timestamp":1758087909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenzhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqian","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","unstructured":"Statement on the fifteenth meeting of the International Health Regulations, (2005) emergency committee regarding the coronavirus disease (COVID-19) pandemic, (2023) World Health Organization\n          \n          \n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243529","article-title":"Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France","volume":"15","author":"Pourcher","year":"2020","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420942020","article-title":"High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study","volume":"32","author":"Funke","year":"2021","journal-title":"Int J STD AIDS"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004323","article-title":"Comparative analyses of COVID-19 in-hospital mortality in people living with HIV during SARS-CoV-2 pre-delta, delta, and omicron waves: data from the who global clinical platform","author":"Inzaule","year":"2025","journal-title":"Aids"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2313","article-title":"Covid-19 vaccines and variants of concern: A review","volume":"32","author":"Hadj Hassine","year":"2022","journal-title":"Rev Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"ofac579","DOI":"10.1093\/ofid\/ofac579","article-title":"A systematic review of COVID-19 vaccine antibody responses in people with HIV","volume":"9","author":"Chun","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003579","article-title":"Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV","volume":"37","author":"Griffin","year":"2023","journal-title":"Aids"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1275843","article-title":"Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/hiv.13537","article-title":"SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis","volume":"25","author":"S\u00f8ndergaard","year":"2024","journal-title":"HIV Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1017\/S095026882300153X","article-title":"Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis","volume":"151","author":"Zhao","year":"2023","journal-title":"Epidemiol Infect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/v16091481","article-title":"Immunogenicity of an inactivated COVID-19 vaccine in people living with HIV in Guangxi, China: A prospective cohort study","volume":"16","author":"Wu","year":"2024","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003176","article-title":"Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29395","article-title":"Safety and immunogenicity of homologous prime-boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study","volume":"96","author":"Wang","year":"2024","journal-title":"J Med Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12981-024-00633-4","article-title":"People living with HIV with the Omicron variant infection have milder COVID-19 symptoms: results from a cross-sectional study","volume":"21","author":"Tan","year":"2024","journal-title":"AIDS Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14080822","article-title":"A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection","volume":"14","author":"Springer","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v16040555","article-title":"Factors associated with neutralizing antibody responses following 2-dose and 3rd booster monovalent COVID-19 vaccination in Japanese people living with HIV","volume":"16","author":"Ngare","year":"2024","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-024-05147-1","article-title":"Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach","volume":"22","author":"Montesi","year":"2024","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29631","article-title":"JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV","volume":"96","author":"Matusali","year":"2024","journal-title":"J Med Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.11.014","article-title":"The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus","volume":"30","author":"Matsumoto","year":"2024","journal-title":"J Infect Chemother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2024.02.004","article-title":"Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV","volume":"57","author":"Liu","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v16050661","article-title":"T-cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy","volume":"16","author":"Datwani","year":"2024","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2309734","DOI":"10.1080\/21645515.2024.2309734","article-title":"Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts","volume":"20","author":"Chittrakarn","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12070785","article-title":"Immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in people living with HIV (PLWH)","volume":"12","author":"Cherneha","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S409147","article-title":"Dynamics of CD4(+) T-cells and neutralizing antibody responses to three consecutive doses of inactivated COVID-19 vaccines in PLWH","volume":"16","author":"Zhang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28428","article-title":"Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV","volume":"95","author":"Zhan","year":"2023","journal-title":"J Med Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28797","article-title":"Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort","volume":"95","author":"Zeng","year":"2023","journal-title":"J Med Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002810","article-title":"A three-dose inactivated SARS-CoV-2 vaccine is sufficient to elicit humoral immune responses in people living with HIV-1","volume":"136","author":"Yu","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11061019","article-title":"Safety and immunogenicity of the inactivated COVID-19 vaccine booster in people living with HIV in China","volume":"11","author":"Yi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002947","article-title":"Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals","volume":"136","author":"Yang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040871","article-title":"SARS-CoV-2 neutralizing antibodies to B.1 and to BA.5 variant after booster dose of BNT162b2 vaccine in HIV patients COVID-na\u00efve and on successful antiretroviral therapy","volume":"11","author":"Vicenti","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11121739","article-title":"Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV","volume":"11","author":"Vergori","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"ofad347","DOI":"10.1093\/ofid\/ofad347","article-title":"Humoral and cellular immune responses of people living with human immunodeficiency virus after 3 doses of messenger RNA BNT162b2 severe acute respiratory syndrome coronavirus 2 vaccine: A prospective cohort study","volume":"10","author":"Tau","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"107959","DOI":"10.1016\/j.isci.2023.107959","article-title":"Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load","volume":"26","author":"Swan","year":"2023","journal-title":"iScience"},{"key":"B39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41522-023-00461-w","article-title":"Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV","volume":"9","author":"Ray","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/v15122427","article-title":"Effect of SARS-coV-2 breakthrough infection on HIV reservoirs and T-cell immune recovery in 3-dose vaccinated people living with HIV","volume":"15","author":"Qu","year":"2023","journal-title":"Viruses"},{"key":"B41","doi-asserted-by":"publisher","first-page":"107915","DOI":"10.1016\/j.isci.2023.107915","article-title":"Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV","volume":"26","author":"Matveev","year":"2023","journal-title":"iScience"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/v15102004","article-title":"Humoral responses elicited by SARS-CoV-2 mRNA vaccine in people living with HIV","volume":"15","author":"Marchitto","year":"2023","journal-title":"Viruses"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13481","article-title":"Immune response to mRNA-based COVID-19 booster vaccination in people living with HIV","volume":"24","author":"Malin","year":"2023","journal-title":"HIV Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264160","article-title":"A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28730","article-title":"Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study","volume":"95","author":"Lu","year":"2023","journal-title":"J Med Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.10.009","article-title":"One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort","volume":"29","author":"Loubet","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1129753","article-title":"Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered","volume":"14","author":"L\u00f3pez-Cort\u00e9s","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29334","article-title":"Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002926","article-title":"Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine","volume":"136","author":"Jin","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204314","article-title":"Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV","volume":"14","author":"Hung","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/v15020575","article-title":"SARS-CoV-2 vaccine-induced T-cell response after three doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 COVAXHIV study)","volume":"15","author":"Alexandrova","year":"2023","journal-title":"Viruses"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314988","article-title":"Quality of T-cell response to SARS-CoV-2 mRNA vaccine in ART-treated PLWH","volume":"23","author":"Tortellini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.09.006","article-title":"Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-na\u00efve people living with HIV","volume":"85","author":"Moussaoui","year":"2022","journal-title":"J Infect"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1049070","article-title":"Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV","volume":"13","author":"Bessen","year":"2022","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081243","article-title":"Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART","volume":"10","author":"Gianserra","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00199-8","article-title":"Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged \u226518 years: a randomised, double-blind, phase 2b trial","volume":"23","author":"Wu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e2","article-title":"COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 States, August 2021-January 2022","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection","volume":"29","author":"Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915805","article-title":"Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4(+) T cells: A pooled data-analysis","volume":"13","author":"Inderbitzin","year":"2022","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143940","article-title":"HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection","volume":"6","author":"Kok","year":"2021","journal-title":"JCI Insight"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745541","article-title":"Immune response to hepatitis B virus vaccine among people living with HIV: A meta-analysis","volume":"12","author":"Tian","year":"2021","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MR0821-464R","article-title":"T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination","volume":"111","author":"Koutsakos","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9464","article-title":"SARS-CoV-2 epitope-specific CD4(+) memory T cell responses across COVID-19 disease severity and antibody durability","volume":"7","author":"Nelson","year":"2022","journal-title":"Sci Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: A decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.xcrm.2022.100640","article-title":"TNF-\u03b1(+) CD4(+) T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies","volume":"3","author":"Van Der Ploeg","year":"2022","journal-title":"Cell Rep Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091569","article-title":"Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis","volume":"10","author":"Kang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00033-9","article-title":"Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study","volume":"9","author":"Netto","year":"2022","journal-title":"Lancet HIV"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kaac027","article-title":"Do side effects to the primary COVID-19 vaccine reduce intentions for a COVID-19 vaccine booster","volume":"56","author":"Geers","year":"2022","journal-title":"Ann Behav Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"100480","DOI":"10.1016\/j.jvacx.2024.100480","article-title":"Global disparities in COVID-19 vaccine booster dose (VBD) acceptance and hesitancy: An updated narrative review","volume":"18","author":"Roy","year":"2024","journal-title":"Vaccine X"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:45:16Z","timestamp":1758087916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2025.1668576"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1668576","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1668576"}}